Table 1

Development, introduction, infectious agent, schedule, and efficacy of vaccines.

Vaccine <mark>(year</mark>) <mark>intr</mark> oduced)	Infectious agent	Kind of vaccine first introduced	Vaccine used in present	Time for vaccination	Need of booster
Smallpox (1798) not injected p	Variola virus ast normal body d	Live vaccinia virus efenses. Like va	N/A ariolation	Stopped in 1972 after eradication	N/A
Anthrax (1881)	Bacillus anthracis	Live, attenuated	Cell-free filtrates of microaerophilic cultures of a toxigenic, non- encapsulated strainof <i>B</i> . <i>anthracis</i> V770-NP1-R	Pre- exposure in adults ≥18 years old; 5 shots over 18 months	Yes; annuall
Rabies (1884)	Rabies virus	Live, attenuated	Inactivated virus	Post- exposure; 4 doses (0, 3, 7, 14)	Not recommende
Typhoid (1896)	Salmonella typhi	Inactivated	Inactivated; live, attenuated	At risk population;	Yes if at risk inactivated:

					inactivated: one dose; live, attenuated: 4 doses every other day	every 2 year live, attenuated: every 5 year	
	Cholera (1884–1896)	Vibrio cholerae	Live, attenuated	Oral, inactivated, killed whole cell of <i>V</i> . <i>cholerae</i>	At risk population; 2 doses 1 week apart	Yes if at risk every 6 months	
a in	Tuberculosis (1927) poverty related France only, pr	<i>Mycobacterium</i> <i>tuberculosis</i> disease, testing oduction 1931	Live, attenuated <i>Mycobacterium</i> <i>bovis</i>	N/A ORAL ONLY ne body defenses,	Single dose for children ot injected pa b/c of parent	Not recommende st natural al objections	
	Yellow fever (1935)	Yellow fever virus	Live, attenuated	Live, attenuated	Single dose ≥9 months old	Not recommende	Insanity launched
	Diphtheria and tetanus toxoids (1930s and 1940s) and acellular pertussis (dtap) ^a (1948)	Corynebacterium diphtheria, Bordetella pertussis, Clostridium tetani	Inactivated	Inactivated	2, 4, 6, 15– 18 months, 4–6 years	Yes; Tdap: 11–12 years; If Tdap not received between 11– 18 years, Tdap dose should be given then followed wit Td booster doses every 10 years	whom and why?
	Poliovirus (1955)	Poliovirus	Inactivated poliovirus	Inactivated and oral, live attenuated	2, 4, 6–18 months	Yes; 4–6 years	
	Influenza (1954–1955)	Influenza virus	Inactivated	Inactivated and live attenuated	Annually	Not recommende	
	Measles, Mumps, Rubella (1971)	Measles, mumps, rubella	Inactivated	Live, attenuated	12–15 months, 4– 6 years	Not recommende	
	Meningococcal (1974)	Neisseria meningitidis	Polysaccharide	Conjugate	11–12 years	Yes; 16 year	
	Pneumococcal (1977)	Streptococcus pneumoniae	Polysaccharide	Polysaccharide- protein conjugate	2, 4, 6, 12– 15 months	Yes; if at risk, ≥65 years old	
	Hepatitis B (1981)	Hepatitis B virus	Plasma derived	DNA recombinant	0, 1–2, 6– 18 months	Not recommende	

Haemophilus influenzae type b (Hib) (1985)	<i>Haemophilus influenzae</i> type B	Polysaccharide	Polysaccharide- protein conjugate	2, 4 months	Yes; 12– 15months
Japanese Encephalitis (1992)	Japanese encephalitis virus	N/A	Inactivated virus	Endemic countries: two-dose series 28 days apart	Yes; if risk (exposure
Varicella (1995)	Varicella zoster virus	Live	Live, attenuated	12–15 months, 4– 6 years	Not recommend(
Hepatitis A (1995)	Hepatitis A virus	Inactivated	Inactivated, whole virus	Two-dose series 6 months apart: 12– 23 months old	Not recommende
Rotavirus (1998)	Rotavirus	Rhesus-based tetravalent rotavirus	RV1: live, oral, attenuated, monovalent human RV5: live, oral, attenuated, pentavalent bovine-human reassortant	RV1: 2, 4 months RV5: 2, 4, 6 months	Not recommend(
Human papillomavirus (2006)	Human papillomavirus	DNA recombinant	DNA recombinant	Three-dose series starting at 11 years old: 0, 1–2, 6 months	Not recommende
Shingles (2006)	Varicella zoster virus	N/A	Live, attenuated	Single dose for people ≥60 years old	Not recommende
H1N1 (2009)	Influenza virus type A	N/A	Inactivated virus	Two doses 4 weeks apart for children aged 6 months-9 years or one dose for adults and children >10 years old	N/A
C) + +